|
KR20130065723A
(ko)
|
2003-06-27 |
2013-06-19 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
|
PE20081216A1
(es)
|
2006-09-01 |
2008-09-04 |
Therapeutic Human Polyclonals Inc |
Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
|
|
HRP20140049T1
(hr)
|
2007-01-05 |
2014-02-28 |
University Of Zürich |
Anti beta-amiloid antitijela i njihova upotreba
|
|
CN102317316B
(zh)
|
2008-12-19 |
2014-08-13 |
帕尼玛制药股份公司 |
人抗α突触核蛋白自身抗体
|
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
EP2542696B1
(en)
|
2010-03-01 |
2016-09-28 |
Caris Life Sciences Switzerland Holdings GmbH |
Biomarkers for theranostics
|
|
JP2013526852A
(ja)
|
2010-04-06 |
2013-06-27 |
カリス ライフ サイエンシズ ルクセンブルク ホールディングス |
疾患に対する循環バイオマーカー
|
|
CA2815181C
(en)
*
|
2010-10-27 |
2020-09-15 |
William Gleason Richards |
Dkk1 antibodies and methods of use
|
|
US9315582B2
(en)
|
2011-02-23 |
2016-04-19 |
Health Research, Inc. |
Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
|
|
EA201391248A1
(ru)
*
|
2011-03-01 |
2014-05-30 |
Эмджен Инк. |
Биспецифические связывающие агенты
|
|
US9255595B2
(en)
*
|
2011-04-29 |
2016-02-09 |
Bae Systems Information And Electronic Systems Integration Inc. |
Optical dome bezel
|
|
SI2723379T1
(sl)
|
2011-06-23 |
2019-03-29 |
Biogen International Neuroscience Gmbh |
Molekule, ki se vežejo ma anti alfa-sinuklein
|
|
WO2013074840A1
(en)
*
|
2011-11-15 |
2013-05-23 |
Allergan, Inc. |
Treatment of dry age related macular degeneration
|
|
UA115789C2
(uk)
*
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
CA2966905A1
(en)
|
2014-11-12 |
2016-05-19 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
MA41115A
(fr)
|
2014-12-02 |
2017-10-10 |
Biogen Int Neuroscience Gmbh |
Procédé de traitement de la maladie d'alzheimer
|
|
CN105821029A
(zh)
*
|
2015-01-04 |
2016-08-03 |
彭霞 |
异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
|
|
SG11201802698XA
(en)
*
|
2015-10-29 |
2018-05-30 |
Hoffmann La Roche |
Transgenic rabbit with common light chain
|
|
CN106928359B
(zh)
*
|
2015-12-30 |
2020-10-13 |
广西医科大学 |
一种CD105纳米抗体Nb59
|
|
CN106928355B
(zh)
*
|
2015-12-30 |
2020-09-29 |
广西医科大学 |
一种CD105纳米抗体Nb184
|
|
US10729771B2
(en)
|
2016-02-10 |
2020-08-04 |
Rutgers, The State University Of New Jersey |
Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infections
|
|
US20200239587A1
(en)
*
|
2016-06-14 |
2020-07-30 |
Cedars-Sinai Medical Center |
Sensitization of tumors to therapies through endoglin antagonism
|
|
CN118370815A
(zh)
|
2017-08-22 |
2024-07-23 |
渤健马萨诸塞州股份有限公司 |
含有抗β淀粉样蛋白抗体的药物组合物
|
|
CN108912212B
(zh)
*
|
2018-06-28 |
2019-08-30 |
中山大学附属口腔医院 |
一种与cd105特异性结合的多肽及其应用
|
|
WO2020106461A2
(en)
*
|
2018-11-08 |
2020-05-28 |
Celldex Therapeutics, Inc. |
Anti-mertk antibodies and methods of use thereof
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
WO2021207433A2
(en)
*
|
2020-04-07 |
2021-10-14 |
The Regents Of The University Of California |
Epitopes of sars-cov-2 neutralizing antibodies
|
|
CN112426526B
(zh)
*
|
2021-01-25 |
2021-04-06 |
北京达熙生物科技有限公司 |
一种nk细胞的制备方法及其在治疗癌症中的应用
|
|
CN112876538B
(zh)
*
|
2021-02-04 |
2022-09-30 |
福建医科大学 |
靶向新生血管标记物cd105的多肽及其应用
|
|
US12162945B2
(en)
|
2021-03-05 |
2024-12-10 |
Immunome, Inc. |
EPHA2 antibodies
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
KR20240135852A
(ko)
*
|
2022-01-24 |
2024-09-12 |
제노백 안티바디 디스커버리 엘엘씨 |
항-alk1 항체 및 그의 사용 방법
|
|
WO2024040194A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
EP4716750A1
(en)
|
2023-05-23 |
2026-04-01 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
AU2024279278A1
(en)
|
2023-05-31 |
2025-12-18 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025045032A1
(zh)
*
|
2023-08-29 |
2025-03-06 |
应世生物科技(南京)有限公司 |
一种靶向cd105的抗体或其抗原结合片段及其应用
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
KR20250174161A
(ko)
*
|
2024-06-04 |
2025-12-12 |
한국과학기술연구원 |
엔도글린 및 메소테린 이중 항원 표적 car 및 이의 용도
|
|
TWI882851B
(zh)
*
|
2024-06-27 |
2025-05-01 |
蔡政育 |
基於專利技術元素整合之專利分析系統及其方法
|
|
WO2026017807A1
(en)
|
2024-07-18 |
2026-01-22 |
Beech Biotech Sa |
Compositions and uses thereof
|
|
WO2026033033A1
(en)
|
2024-08-07 |
2026-02-12 |
Beech Biotech Sa |
Compositions and uses thereof
|